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EX VIVO AND IN VIVO METHODS AND
RELATED COMPOSITIONS FOR
GENERATING HEMATOPOIETIC STEM
CELL POPULATIONS

going full differentiation. HSCs can differentiate into

hematopoietic progenitor cells (“HPCs”) that can further dif
ferentiate into clonogenic cells, or cells of a single lineage.
For example, the differentiation of common lymphoid pro

genitors (“CLPs”) can produce T lymphocytes (“T cells”), B
lymphocytes (“B cells”), and natural killer cells (“NKs”). The
differentiation of common myeloid progenitors (“CMPs”)
can generate blood cells of other lineages, including erythro
cytes, macrophages, granulocytes, and platelets. The mainte

CROSS-REFERENCES

This application is a non-provisional application that
claims priority under 35 U.S.C. §119 to US. Provisional
Application No. 60/722,755 entitled MANIPULATION OF

nance of mature blood-bome cells in the peripheral circula

ADULT STEM CELL POPULATION SIZES BY LATEXIN

tion is critical for various processes, including oxygen

and ?led on Sep. 30, 2005, the entire content of Which is

delivery and immunological protection.

hereby incorporated by reference.

Bone marroW transplantation (“BMT”) and hematopoietic
stem cell transplantation (“HSCT”) can be effective for the
treatment of diseases of the blood, diseases of the bone mar

STATEMENT OF GOVERNMENT INTEREST

roW, cancers of the blood, and cancers of the bone marroW,

This invention has been made With Government support

including various types of anemia, leukemia, and immuno
logical disorders. For example, obtaining HSCs by bone mar

under grant number ROI AG024950, aWarded by the National
Institute on Aging. The government has certain rights in the
20

invention.
TECHNICAL FIELD

The present invention relates to methods for regenerating

adult hematopoietic stem cells (HSCs) and related composi
tions by reducing/inhibiting latexin expression and/ or latexin

25

roW harvesting from donors can be technically challenging in
that harvesting suf?cient material from the bone marroWs of

donors involves multiple insertions of large needles to obtain
suf?cient amount of stem cells. Methods for regenerating
HSCs can be useful for treating patients affected by various
types of disorders, diseases, or cancers that deleteriously
affect the number of endogenous HSCs Within a patient.

activity.
SUMMARY OF THE INVENTION
INCORPORATION-BY-REFERENCE & TEXTS
30

The material on the accompanying CD-R is hereby incor

porated by reference into this application. The accompanying
compact disc contains one ?le, 1028750-000249
HSCS.ST25.txt, Which Was created on Oct. 2, 2006. The ?le
named 1028750-000249 HSCS.ST25.txt is 5 KB. The ?le can
be accessed using Microsoft Word on a computer that uses
WindoWs OS.

An ex vivo method for producing a reneWed population of

hematopoietic stem cells (HSCs) is provided, in Which a ?rst
HSC population from a donor is obtained, the ?rst HSC
population is contacted With an antagonist that reduces
latexin expression and/ or latexin activity, and the HSC popu
35

lation is cultured under in vitro conditions that can promote
cell proliferation and/or inhibit apoptosis to obtain a second
HSC population that comprises a progeny of the ?rst HSC

population.
BACKGROUND OF THE INVENTION
40

Hematopoiesis is a complex process for producing mul
tiple and distinct lineages of blood-borne cells throughout the
life span of an organism. Hematopoietic stem cells (“HSCs”)
represent a subset of undifferentiated cells that resides pre
dominantly in the bone marroW of adult mammals. HSCs, as
a population, are capable of self-reneWal by maintaining a
suf?cient number of HSCs Within an organism’s bone mar

45

roW as a reservoir of uncommitted cells that can be further

differentiated into various types of neW blood cells. Such
neWly generated blood cells emerge from the bone marroW
and enter the circulatory system in order to continuously

50

A method for reconstituting a recipient host With a HSC
population generated ex vivo is provided, in Which a ?rst HSC
population from a donor is obtained, the ?rst HSC population
is contacted With an antagonist that reduces latexin expres
sion and/or latexin activity, the HSC population is cultured
under in vitro conditions that can promote cell proliferation
and/or inhibit apoptosis to obtain a second HSC population
that comprises a progeny of the ?rst HSC population, and the
second HSC population is transplanted to the recipient ho st in
need of HSC reconstitution.
A method for reconstituting a recipient host With a HSC

population generated in vivo is provided, in Which the recipi
ent host is administered With a pharmaceutical composition

replace mature/ aging circulating blood cell types. The ability

comprising an antagonist that reduces latexin expression and/

of HSCs, as a population, to differentiate and to give rise to

or latexin activity.

cells of multi-lineages is critical for the preservation of an

organism.

55

BRIEF DESCRIPTION OF DRAWINGS

In order for the maintenance of steady-state hematopoiesis,
a balance must be achieved betWeen the rate of self-genera

tion (i.e., for maintaining a steady supply of HSCs) and the
rate of differentiation (i.e., for replenishing senescent cells).
Hematopoiesis occurs as a developmental continuum in that a

60

given population of HSCs is representative of a heteroge
neous mixture of cells, mainly composed of long-term HSCs
(“LT-HSCs”) and short-term HSCs (“ST-HSCs”). LT-HSCs
are stem cells that have the capacity for self-reneWal through
out the life span of an organism. HoWever, ST-HSCs exhibit
transient self-reneWal properties for a limited period of time
(e. g., typically less than 8 Weeks in a mouse) prior to under

65

FIG. 1 illustrates various biochemical pathWays mediated
by latexin that may be involved in the regulation of HSC
proliferation in mammals, as described in Example 1.
FIG. 2 illustrates a genomic map of congenic intervals
identi?ed in reciprocal Chr.3 congenic mouse strains, as
described in Example 1.
FIG. 3 illustrates a genome-Wide linkage analysis based on
GeneNetWork that associates the trait regulating HSC popu
lation siZe With three quantitative trait loci (QTL) on Chro
mosomes (Chr) 3, 5, and 18, respectively, as described in

Example 4.

US 8,110,184 B2
3

4

FIG. 4A illustrates the CAFC day 35 frequency observed
for femur cells of Chr3 congenic mice compared to back
ground mice, as described in Example 5.
FIG. 4B illustrates the CAFC day 35 frequency observed
for LSK cells of Chr3 congenic mice compared to back
ground mice, as described in Example 5.

(HSCs) Within a patient in need of HSC reneWal. For
example, the present methods are useful for the treatment of
patients affected With disorders, diseases, and/ or cancers that

FIG. 4C illustrates the effect of D2 alleles on the number of

plated for treatment by the present methods and compositions

deleteriously compromise the number of endogenous HSCs
and differentiated forms of such HSCs Within patients.
Examples of disorders, diseases, and/or cancers contem

long-term repopulating HSCs in BD Chr3 mice, as described
in Example 5.

cancers of the blood, and cancers of the bone marroW, includ

FIG. 5A illustrates that D2 alleles confer an increase in
HSC replication and that B6 alleles confer a decrease in HSC

ing various types of anemia, leukemia, immunological disor
ders, thalassemia major, sickle-cell disease, myelodysplastic

include diseases of the blood, diseases of the bone marroW,

syndrome, lymphoma, aplastic anemia, and multiple

replication, as described in Example 6.
FIG. 5B illustrates the effect of Chr 3 QTL on the cell-cycle
kinetics of hematopoietic progenitor cells (HPCs), as
described in Example 6.
FIG. 5C illustrates that D2 alleles of the Chr 3 QTL confer
HSCs With higher self-reneWal capability, as described in

myeloma. Patients that may bene?t from treatments that uti
liZe the present methods and related compositions include
candidates for bone marroW transplantation (“BMT”) and

hematopoietic stem cell transplantation (“HSCT”). Trans

Example 8.

plantation therapies can be effective for the treatment of vari
ous types of leukemia and any disorder/disease/cancer for
Which patients are subjected to radiotherapy and/ or chemo
therapy. The reneWed or regenerated population of HSCs that
can be induced by the present methods and compositions are

FIG. 5E illustrates the effect of Chr 3QTL on apoptosis of
LSK cells in steady-state B6 D2 and Chr3 congenic bone

useful for various applications, including regenerative medi
cine, tissue engineering, tissue repair, cancer therapy, and

Example 7.
FIG. 5D illustrates bone marroW LSK cells subject to apo

ptosis as detected by Annexin V-staining, as described in

20

gene therapy. As described in the folloWing embodiments, a

marroWs, as described in Example 8.

FIG. 6A illustrates Lxn mRNA expression in congenic
LSK cells compared With B6 and D2 cells, as described in

25

recipient host (i.e., a patient) can be induced to proliferate
and/or to suppress apoptosis by providing antagonistic com
pounds/compositions that can inhibit latexin expression and/
or latexin activity.

Example 10.
FIG. 6B illustrates quantitation of Lxn transcripts by real
time PCR in peripheral blood leukocytes, Whole bone mar
roW, Lin-negative bone marroW cells, and LSK stem cells, as

30

I. De?nitions

described in Example 11.
FIG. 6C illustrates immunoreactivity betWeen the anti
mouse LXN antibody and a protein (29 kD) from bone mar
roW cells by a Western Blot, as described in Example 12.
FIG. 6D illustrates the levels of LXN protein in Whole bone
marroW and Lin-negative cells, as described in Example 12.
FIG. 7A illustrates various QTLs that may be involved in

the regulation of Lxn expression, as described in Example 13.
FIG. 7B illustrates a CpG island analysis in the upstream
sequence of Lxn open-reading frame, as described in

As used throughout the speci?cation and the appended
claims, the terms listed beloW have the folloWing meanings,
35 Wherein “a” means one or more:

The terms “hematopoietic stem cells” (“HSCs”) refer to a

heterogeneous mixture of undifferentiated progenitor stem

cells, mainly composed of long-term HSCs (“LT-HSCs”) and
40

Example 13.
FIG. 8A illustrates a schematic for in vitro infection of
bone marroW cells With retroviral vectors containing either

GFP or Lxn (Lxn-GFP), and subsequent transplantation into
irradiated mouse recipients, as described in Example 14.
FIG. 8B illustrates results of a Western blot analysis of
GFP+ cells sorted from the BM of the recipient mice trans
planted With either Lxn-GFP or GFP-transduced cells, as

described in Example 14.
FIG. 8C illustrates results of CAFC day 35 frequency assay

given HSC population obtained from a donor or Within a

45

short-term HSCs (“ST-HSCs”). LT-HSCs are undifferenti
ated stem cells that have the capacity for self-reneWal
throughout the life span of an organism. ST-HSCs are undif
ferentiated stem cells that have the capacity for self-reneWal
for a limited time prior to full differentiation into a speci?c
lineage. For example, HSCs can differentiate into hematopoi
etic progenitor cells (“HPCs”) that can further differentiate
into clonogenic cells, or cells of a single lineage, that repre
sent a subset of a hematopoietic lineage. HSCs include non

embryonic stem cells isolated from post-natal animals. HSCs
include “pluripotent adult stem cells” isolated from the bone
50

marroWs of mammals that are capable of differentiating into

of D2 bone marroW cells transduced With either GFP control
or Lxn-GFP, as described in Example 14.

tissues of all three germ or dermal layers, such as the meso

FIG. 8D illustrates results of long-term repopulating cells
(LTRC) frequency assay of BD Chr.3 congenic BM cells

refers to a stem cell that exhibits the capacity to groW into any

transduced With either GFP control or Lxn-GFP, as described

derm, endoderm, and ectoderm. A “pluripotent stem cell”

55

Within a tissue. HSCs include “multipotent stem cells” that
exhibit the capacity to groW into any subset of cells that
constitute an organism. HSCs include undifferentiated stem
cells that exhibit a distinct pro?le of cell surface markers,

in Example 14.
FIG. 9A illustrates exemplary SiRNAs transfected into
NIH3T3 cells, as described in Example 15.
FIG. 9B illustrates the results of sequence-speci?c SiRNA
mediated inhibition of latexin mRNA expression in mouse
adult stem cells that resulted in HSC proliferation and HSC
apoptotic inhibition, as described in Example 15.

60

1+ Lineage- c-kit"; or CD 150+ CD48- Sca-l+ Lineage
express the combination of human counterparts for these
65

Various embodiments provide methods and related com

including the folloWing combination of markers: Thy-1Z0 Sca
c-kit"; or Thy-1Z0 CD150+ CD48“ Sca-l+ Lineage“ c-kit+
(Kiel et al., Cell, Vol. 121, p 1109-1121 (2005)). HSCs that

DETAILED DESCRIPTION OF THE INVENTION

positions useful for reconstituting hematopoietic stem cells

type of cell that constitutes an organism. A pluripotent cell
can be self-reneWing and can remain dormant/quiescent

markers are preferably contemplated. The folloWing refer
ences are herein incorporated by reference in their entirety:
Cheshier et al., P.N.A.S., Vol. 96, p 3120-3125 (1999); Eck

US 8,110,184 B2
5

6

feldt et al., Nature, Vol. 6, p 726-737 (2005); Wright et. al.,
Science, Vol. 94, p 1933-1936 (2001); and Preston et al., J.
Clin. Pathol. Vol. 56, p 86-96 (2003).

ing HSC cell proliferation (i.e., HSC self-reneWal) and/or by
suppressing HSC apoptosis, as seen in BD Chr3 congenic
mice. In contrast, the B6 alleles conferred a decrease in HSC

population size. Differential expression levels conferred by

The term “?rst HSC population” refers to HSCs obtained
from a donor, Wherein the ?rst HSC population expresses cell

these alleles correlated With the latexin (“Lxn”) gene locus.
Differential latexin expression levels Were shoWn to inversely
correlate With HSC population size, based on experimental

surface markers as described supra.

The term “second HSC population” refers to the progeny of

the ?rst HSC population produced by in vitro cell prolifera
tion under in vitro conditions, Wherein the second HSC popu

data obtained utilizing oligonucleotide arrays (e. g., microar
rays), real-time PCR, and Western blots. Ectopic expression

lation expresses cell surface markers as described supra.
The term “latexin” (“Lxn”) refers to the Lxn gene, iso

of latexin protein from a retroviral construct resulted in a

decrease in stem cell population size. Clusters of single nucle
otide polymorphisms (SNPs) Were identi?ed upstream of the

forms/variants of the Lxn gene, and gene products derived
from the Lxn gene, including messenger RNA and protein.

Lxn transcriptional start site. At least tWo of these clusters
appear to be associated With potential binding sites for tran

The sense-strand of a human latexin cDNA is provided as

SEQ ID NO: 1. A human latexin protein sequence is provided

scription factors involved in hematopoietic stem cell regula
tion. Thus, promoter polymorphisms betWeen B6 and D2

as SEQ ID NO:2. Latexin isoforms/variants include genes

containing exon sequences having at least about 70%, 75%,
80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence
similarity to SEQ ID NO: 1; genes containing exon sequences

having at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%,

alleles appear to affect Lxn gene expression, and conse

quently, to in?uence HSC population size. The results of
20

described in Examples 1-15.

97%, 98%, or 99% sequence identity to SEQ ID NO: 1; those
sequences encoded by genes containing exon sequences hav

Latexin Was identi?ed initially as an antigen expressed
Within the rat cerebral cortex. Latexin mRNA and protein (29
kDa) have been shoWn by others to be expressed in neural and

ing at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%,
97%, 98%, or 99% sequence similarity to SEQ ID NO:1;
those sequences encoded by genes containing exon

sequences having at least about 70%, 75%, 80%, 85%, 90%,
95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID
NO: 1; those sequences having at least about 70%, 75%, 80%,
85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence similar
ity to SEQ ID NO:2; and those sequences having at least
about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or
99% sequence identity to SEQ ID NO:2. Latexin isoforms/
variants include mammalian homologs listed in Tables 1-3.
Examples of latexin isoforms/variants include the carbox
ypeptidase inhibitor (CARIN) described in US. Pat. No.

these experiments are presented in FIGS. 1-9 and are further

25

non-neural tissues. Latexin exhibits inhibitory activity

against rat carboxypeptidaseAl (“CPA1”), carboxypeptidase
A2 (“CPA2), and mast-cell CPA (Uratani et al., Biochem. 1.,
Vol 346: 817-826 (2000). CPA and CPB are pancreatic zinc
30

containing proteolytic enzymes that catalyze the hydrolysis
of the carboxyl-terminal peptide bond Within polypeptide
chains. Carboxypeptidase activities canbe regulated either by
endogenous protein inhibitors or by enzymatic cleavage of a
segment of a propeptide that releases the active form of the

35

carboxypeptidase. Both latexin and Tissue Carboxypeptidase
Inhibitor (TCl) are examples of endogenous protein inhibi

5,998,373.

tors of carboxypeptidases. Latexin and TCI contain several

The term “antagonist” refers to any compound or compo
sition that can inhibit the expression and/or the activity of

potential phosphorylation sites, and both are expressed and
localized in the cytosol of a number of tissues, including the
brain, the lung, and the digestive tract.

latexin and latexin isoforms, including sequence-speci?c
polynucleotides that can interfere With the transcription of

40

endogenous latexin gene; sequence-speci?c polynucleotides
that can interfere With the translation of latexin mRNA tran

scripts (e.g., siRNAs, ribozymes); sequence-speci?c

similarity betWeen latexin and cystatins that inhibit cathep

polypeptides that can interfere With the protein stability of

latexin, the enzymatic activity of latexin, and/or the binding

FIG. 1 illustrates various biochemical pathWays mediated
by latexin that may be involved in the regulation of HSC
proliferation in mammals. Lxn is the only knoWn endogenous
carboxypeptidase A (CPA) inhibitor in mammals. Structural

45

sins in the lysosomal protein degradation pathWay suggests

activity of latexin With respect to substrates and/or regulatory
proteins; and small molecule compounds that can interfere

an in?ammatory role of latexin in activated macrophages.
Thus, latexin may be involved in the metabolism of speci?c

With the protein stability of latexin, the enzymatic activity of
latexin, and/or the binding activity of latexin. An effective

proteins that are essential for HSC functions. Lxn appears to

antagonist can promote HSC proliferation by at least 25%,

exhibit tWo potential Ca2+/calmodulin-dependent protein
50

30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%,
80%, 85%, 90%, 95%, or 100%. An effective antagonist can

suppress HSC apoptosis by at least 25%, 30%, 35%, 40%,

45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%,
95%, or 100%.

55

kinase sites and one c-GMP-dependent protein kinase phos
phorylation site. Thus, the c-GMP/PKG and/or calcium/
calmodulin signaling pathWays may be involved in the Lxn
mediated regulation of HSCs. The physical structure of
latexin includes tWo nearly identical domains that have high
conformational homology With the cystatins that can inhibit

cathepsins in the lysosomal protein degradation pathWay.
11. Regulation of Cell Cycling, Apoptosis and
Proliferation of Hematopoietic Stem Cells (HSCs)
Mediated by Latexin
The present inventors have identi?ed a quantitative trait
loci (“QTL”) that confers variation in HSC numbers in young

Thus, Lxn appears to have an in?ammatory role in activated
macrophages, and to be involved in the metabolism of spe
ci?c proteins that are essential for HSC functions. The
c-GMP/ PKG and/ or calcium/calmodulin signaling pathWays
may be involved in Lxn-mediated regulation of HSCs based
on the fact that Lxn contains tWo potential Ca2+/calmodulin

and adult C57BL/ 6 (B6) and DBA/2 (D2) mice. By utilizing
reciprocal Chromosome 3 congenic mice derived from these

protein kinase phosphorylation site. These possible pathWays
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tWo parental strains, such as B.D Chr3 and DB Chr3 mice,
the present inventors have demonstrated that intro gressed D2
alleles confer an increase in HSC population size by enhanc

dependent protein kinase sites and one c-GMP-dependent
65

may act synergistically or independently in the regulation of

HSC cycling, apoptosis, and/or proliferation that affect HSC
population size.

